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ABSTRACT 
 
 
Advances in imaging technology have driven the rapid expansion in the use of computed 
tomography in the assessment of coronary atherosclerotic plaque. Current guidelines 
recommend coronary CT angiography as the first line diagnostic test for patients presenting 
with stable chest pain based on a rapidly growing evidence base. There is a growing need to 
refine current methods for diagnosis and risk stratification to better individualise preventative 
therapies. Imaging assessments of high-risk plaque with computed tomography can be used 
to differentiate stable from unstable patterns of coronary atherosclerosis and potentially to 
improve patient risk stratification. This review will focus on coronary imaging with 
computed tomography with a specific focus on the detection of coronary atherosclerosis, 
high-risk plaque features, and the implications for patient management. 
 
KEYWORDS 
1. Coronary CT angiography 
2. Atherosclerosis 
3. High-risk Plaque 
4. Positron Emission Tomography 
 
ABBREVIATIONS 
1. CT: Computed Tomography 
2. TCFA: Thin Cap Fibrous Atheroma 
3. PET: Positron Emission Tomography 
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4. TPSO : Translocator proteins  
5. LDL: Low Density Lipoproteins 
6. PKS9: Proprotein convertase subtilisin–kexin type 9  
 INTRODUCTION 
 
Cardiovascular disease remains the leading causes of death globally, placing a huge 
economic burden on health services worldwide (Mendis et al., 2015). Subsequently, there 
remains major interest in refining our current methods for diagnosis and risk stratification to 
better individualise preventative therapies. Atherosclerosis is the main pathophysiological 
process responsible for cardiovascular disease. It is a systemic multifocal process that starts 
early in life and has a long quiescent phase prior to the manifestation of clinically overt 
disease. The majority of patients presenting acutely with a thrombotic cardiovascular event 
have no previous manifestation of their disease (Ambrose et al., 1988; Myerburg et al., 1992). 
This silent disease process presents a tremendous diagnostic challenge, underpinning the 
global burden of cardiovascular disease.  
 
Coronary computed tomography (CT) angiography has emerged as a powerful tool for the 
diagnosis of coronary artery disease. As well as the assessment of luminal stenosis, it allows 
direct plaque visualisation and potential identification high-risk plaque. Myocardial infarction 
is most commonly caused by rupture of atherosclerotic plaque and plaques that rupture have 
certain common characteristics that together define the vulnerable plaque (Kolodgie et al., 
2001). Vulnerable plaques have played an integral role in of our understanding of 
atherosclerosis and cardiovascular disease, with extensive research conducted to better 
characterise and identify these lesions. This identification, in combination with timely 
intervention prior to the occurrence of an acute event, could potentially comprise a treatment 
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strategy for reducing the morbidity and mortality of atherosclerotic disease.  This review will 
focus on the use of computed tomography to detect coronary atherosclerosis, high-risk plaque 
features, and the implications for patient management. 
THE CONCEPT OF THE VULNERABLE PLAQUE 
 
The coronary artery plaque that lies at the core of coronary heart disease has been the subject 
of intensive research. Pathological intimal thickening is the first progressive stage of 
atherosclerosis and is characterised by extracellular lipid accumulation. Macrophage 
infiltration into the lipid pool heralds the formation of fibroatheroma, with associated necrotic 
core and overlying nascent fibrous cap (Stary et al., 1994). Foam cell death promotes 
atheroma expansion, and extracellular binding of lipids to collagen fibres and proteoglycan. 
As the fibroatheroma progresses, the extracellular accumulation of lipids causes severe 
inflammatory reactions in the arterial wall, with lymphocytic infiltration and depletion of 
extracellular matrix with subsequent expansion of the lipid core. The secretion of proteases 
by macrophages and other immune cells can cause weakening of connective tissue in the 
atheroma with disruption of the fibrous cap  and formation of a thin cap fibrous atheroma 
(Burke et al., 1997). The vulnerable plaque is thus characterised by a large necrotic core, a 
thin (<65 μm) and inflamed fibrous cap, large plaque volume, inflammatory cell infiltration 
and spotty calcification (Burke et al., 1997). 
 
As atherosclerotic plaques progress, the affected vessel may undergo positive remodelling 
with degradation and reorganisation of the extracellular matrix (ECM) scaffold of the vessel 
wall, a process regulated by matrix metalloproteinases (MMPs) (Bonnans et al., 2014)  which 
also have an established role in the pathophysiology of plaque rupture (Schoenhagen et al., 
2000). Positive remodelling may be a sign of an early proliferative process, allowing 
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expansion of the plaque contents in an outward direction, that mitigates stenosis and 
preserves blood flow. These plaques, are thought to be particularly “vulnerable” to rupture 
(Varnava et al., 2002) (Schoenhagen et al., 2000) 
 
Plaque rupture is the commonest complication of atherosclerosis, accounting for 60-70% of 
culprit lesions in acute myocardial infarction (Naghavi et al., 2003). The majority of clinical 
events caused by plaque rupture arise from non-obstructive plaques (Virmani et al., 2002). 
This may explain why percutaneous coronary intervention in optimally treated patients with 
stable angina may relieve chest pain symptoms but without reducing the risk of death, non-
fatal myocardial infarction or major adverse cardiovascular events (Boden et al, 2007; Sedlis 
et al, 2015). Indeed, plaques prone to rupture share similar morphological characteristic to the 
aforementioned thin cap fibrous atheroma (TCFA) (Virmani et al., 2006) (Kolodgie et al., 
2001). These findings and their imaging equivalents are found in patients who appear to be at 
increased risk of future adverse clinical events, forming the basic rationale of vulnerable 
plaque imaging.  However, this prognostic information does not appear to hold true at the 
level of plaque, with data from the PROSPECT trial (A Prospective Natural-History Study of 
Coronary Atherosclerosis) suggesting that the vast majority of high-risk thin-capped 
fibroatheromatous plaques did not result in clinical events (Stone et al, 2011).  Indeed, most 
plaque rupture events appear clinically silent, resulting in a healing response and plaque 
growth rather than infarction (Davies, 2000). 
 
This raises questions about the value of identifying the vulnerable plaque. If the majority of 
such plaques do not in fact cause clinical events and more likely to heal silently rather than 
rupture, what is the value in their detection? Some have argued that this concept may work 
better at the patient level (Naghavi et al., 2003) – giving rise to the concept of the “vulnerable 
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patient”. Patients with a predisposition to develop high-risk plaque characteristics will tend to 
form many over time. Whilst the majority of individual plaques will heal, the patient will be 
at greater risk of a plaque ultimately rupturing at a moment of increased thrombogenicity and 
causing an acute myocardial infarction.  Therefore, our approach to CT assessment of 
coronary plaque needs to take into account this complex interaction between the anatomical, 
molecular and biomechanical factors that determine sudden symptomatic plaque disruption, 
the overt patient burden, and its downstream sequelae.  
 
 
IMAGING TARGETS 
 
Obstructive vs Non-Obstructive Disease 
Our clinical approach to coronary atherosclerosis has, for many decades, been based around 
the detection and treatment of obstructive luminal stenoses and the myocardial ischemia that 
can ensue (Neumann et al., 2019). Invasive coronary angiography with or without invasive 
functional assessments is perceived to be the gold standard, although cardiac computed 
tomography is increasingly being employed for the same purpose, avoiding the need for an 
invasive procedure (Figure 1).  Technical advances, such as more sensitive detectors, faster 
gantry speed rotation, and superior image reconstruction software, have resulted in improved 
temporal and spatial resolution with better imaging quality and fewer partial volume effects 
and motion artefacts. Furthermore, recent breakthroughs in post-processing and analysis, 
such as radiomics (quantitative measures of image texture), allow us to obtain more 
information from scans. Using novel data analytic techniques, such as machine learning, 
distinct patterns in radiological images (Kolossváry et al., 2019) can be identified that would 
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otherwise go undetected. This has the potential to revolutionise imaging and the field of 
precision medicine.   
 
 
Assessment of luminal stenosis by coronary CT angiography has demonstrated powerful 
prognostic capability (Min et al., 2007). Current clinical interpretation, and quantification of 
coronary arterial stenosis are based on the 2014 Society of Cardiovascular Computed 
Tomography (SCCT) reporting guidelines (Wu and Wu, 2015) . Obstructive disease is 
defined as a luminal stenosis of over 70%, a definition that has been adopted in landmark CT 
trials. Coronary Artery Disease-Reporting and Data System (CAD-RADS) is a newer 
standardised reporting system for coronary CT angiography which classifies results based on 
the severity of stenosis and to link these data to clinical patient management. Degree of 
stenosis, plaque morphology, image quality, stents, and coronary artery bypass grafts are 
evaluated to decide the final CAD-RADS category (CAD-RADS 0- CAD-RADS 5). Whilst 
the CAD-RAD scoring provides important prognostic information in patient undergoing 
evaluation for coronary artery disease (Xie et al., 2018) , this needs to be confirmed using 
larger registries, and all analysis should incorporate the presence of modifiers (vulnerability, 
stent and CABG) in addition to stenosis severity. Whilst this scoring system has been 
endorsed by the SCCT, ACR and NASCI (Cury et al., 2016), it remains mainly a research 
tool and requires further refinement prior to routine clinical implementation. 
 
Coronary CT angiography carries important prognostic information in addition to the 
detection of obstructive disease. It  also detects non-obstructive disease which is the dominant 
cause of major adverse cardiovascular events, and would benefit from early risk modification 
(Jespersen et al., 2012).  In the largest randomised trials to date, approximately half of 
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patients with subsequent adverse clinical events did not have obstructive coronary artery 
disease (Douglas et al., 2015; SCOT-HEART investigators, 2015). This is in fact consistent 
with the pathological studies described above and also well-established data demonstrating 
that the majority of myocardial infarctions arise from non-obstructive lesions on antecedent 
angiography (Farb et al., 1996).  One explanation for this is that as atherosclerotic plaques 
progress the affected vessel may undergo positive remodelling with expansion of the plaque 
contents in an outward direction, that mitigates stenosis and preserves blood flow even in 
lesions with a high plaque burden: so called Glagovian remodelling (Hadamitzky et al., 
2013). In fact, the magnitude of coronary atherosclerosis on coronary CT angiography is an 
important prognostic factor with multiple studies confirming the predictive value of 
segmental plaque burden above and beyond the degree of stenosis (Min et al., 2007); 
(Hadamitzky et al., 2013).  
 
Landmarks trials documenting the mortality benefit of coronary artery bypass grafting for 
extensive obstructive disease, are based on the premise that prognosis is related to the 
presence and number of obstructive stenosis (Min et al., 2011). However, patients with 
widespread non-obstructive coronary artery disease have similar event rates when compared 
with patients with localized obstructive disease (Bittencourt et al., 2014).  Moreover, the  
COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug 
Evaluation) (Boden et al., 2007) and BARI-2D (Bypass Angioplasty Revascularization 
Investigation 2 Diabetes)  (Boden et al., 2007; BARI 2D Study Group et al., 2009) trials 
demonstrated that percutaneous coronary intervention failed to reduce the risk of myocardial 
infarction despite effective relief of obstructive disease and consequent ischemia. As a 
consequence, questions are being asked about the central role that assessments of luminal 
stenosis and myocardial ischemia play in the management of patients with suspected 
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coronary artery disease. Accordingly, there has been growing interest in alternative imaging 
strategies targeting different aspects of the atherosclerotic disease process.  
 
Recent advanced in computational fluid dynamics, such as fractional flow reserve (FFR)-CT 
and endothelial shear stress-CT, can enable physicians to gather not only anatomical but also 
morphologic and derived physiologic data using one non-invasive imaging test (Choi et al., 
2015) (Norgaard et al., 2014). These novel CT-based approaches have been validated in 
clinical trials and are associated with atherosclerotic plaque characteristics  and may be 
helpful to assess the future risk of plaque rupture and to determine treatment strategy 
(Nakazato et al., 2016). 
 
 
Plaque Burden 
One strategy has been to quantify the total atherosclerotic plaque burden. The rationale being 
that the more plaques a patient has, the more likely it is that a plaque rupture will occur and 
cause a clinical event. Coronary artery calcium scoring measures macroscopic calcification in 
the coronary arteries and provides an reliable surrogate marker of  coronary plaque burden. It 
has repeatedly been shown to correlate with clinical outcome (Greenland et al., 2004); 
(Budoff et al., 2007). There have been multiple studies examining the very low event rates in 
patients with coronary artery calcium scores of zero (Sarwar et al., 2009); (Blaha et al., 
2016). In asymptomatic patients, the absence of calcium reliably excludes obstructive 
coronary artery stenosis, although more caution is required in symptomatic patients where 
non-calcific plaques are observed with greater frequency.  On this basis, the most recent 
National Institute of Clinical Excellence (NICE) chest pain guidelines recommend coronary 
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CT angiography rather than coronary artery calcium scoring in symptomatic patients (NICE 
CG95, 2016).  
 
The presence of calcium confirms the presence of coronary atherosclerotic plaque, with 
increasing scores identify increasing plaque burden and increased cardiovascular risk. 
Moreover, when added to traditional risk scores, coronary artery calcification has the ability 
to provide incremental risk predictive information to re-classify individuals into higher or 
lower risk groups (Silverman et al., 2014); (Polonsky et al., 2010). This has the benefit of 
facilitating more effective healthcare resource utilisation by minimising therapy in low-risk 
groups and allowing for more appropriate therapy in high-risk groups thereby improving 
outcomes (Rozanski et al., 2011). Coupled with its non-invasive nature, minimal radiation 
exposure and no requirement for patient preparation, its powerful predictive ability makes 
coronary calcium scoring an attractive option for population screening. Despite its many 
strengths, not least the decades of prognostic data supporting their value for clinical risk 
prediction, traditional calcium scores using the Agatston score fail to incorporate information 
about the number and size of calcified lesions, and are weighted for increasing calcium with 
higher calcium density. This does seem counterintuitive in the context of histological data 
suggesting that plaques with high calcium density have smaller lipid cores, whilst plaques 
with low calcium density have large lipid cores and positive remodelling. 
 
Progression in CT calcium scores is more difficult to interpret. Statins, whilst well 
established in the prevention of coronary events, appear to increase not decrease the CT 
calcium score (Wong et al., 2004); (Arad et al., 2005). This perhaps reflects a healing 
response to statins which may play a role a role in the conversion of non-calcified plaque to 
calcified plaque, thereby stabilising potentially vulnerable plaques.  This highlights an 
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important limitation of CT calcium scoring: namely this approach is actually targeting a more 
stable form of plaque that itself is less prone to rupture or cause clinical events. The rationale 
extension of plaque burden imaging is to consider not only how much plaque a patient has 
but also what kind of plaque they have and whether the disease process in that area is active 
or not. These two approaches are considered in the following sections.  
 
Plaque Morphology 
The sub-millimeter spatial resolution of coronary CT angiography is capable of imaging not 
only the lumen, but also the coronary artery wall. This makes CT a promising alternative to 
the more invasive intravascular imaging with studies demonstrating close correlation between 
coronary CT angiography and intravascular imaging findings of thin-cap fibroatheromas for 
the detection of high-risk plaque (Voros et al., 2011) (Tanaka et al., 2008). At the very least, 
CT angiography is able to differentiate between calcific, partially calcified (mixed)  and non-
calcified coronary plaque, thereby potentially overcoming an important limitation of CT 
calcium scoring (Plank et al., 2014).  Non-calcified coronary plaques identified by coronary 
CT angiography portend a poorer prognosis (Hulten et al., 2011; Hou et al., 2012). 
 
Coronary CT angiography can provide even more detailed morphological information. There 
are several well described coronary CT angiographic features of high-risk plaque which 
reflect the underlying pathological changes (Figure 2). These are low-attenuation (<30 
Hounsfield Units), positive remodelling (commonly defined as a remodelling index >1.1), 
spotty calcification and the napkin-ring sign (low-attenuation plaque core with a rim of 
higher attenuation).  There is a large body of observational evidence demonstrating the 
prognostic power of coronary CT angiography assessments of high-risk plaque in both stable 
and acute coronary presentations.  Motoyama and colleagues identified that the presence of 
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high-risk plaque characteristics was  associated with acute coronary syndrome (Motoyama et 
al., 2007).  Recent analyses from the two largest randomised trials of coronary CT 
angiography in patients with suspected stable coronary disease – the Scottish Computed 
Tomography of the Heart (SCOT-HEART) and Prospective Multicenter Imaging Study for 
Evaluation of Chest Pain (PROMISE) trials – have added further weight to the prognostic 
power of CT assessments of high-risk plaque (Ferencik et al., 2018); (Williams et al., 2019).  
We will explore this further in the following sections. 
  
While these data support the theory that patients with high-risk plaque features are at 
increased risk of future events, they highlight an important caveat: that no study of high-risk 
plaque identification has yet demonstrated incremental prognostic benefit over and above the 
calcium score. As such, there is currently little evidence to support the inclusion of high-risk 
plaque features in guidelines and recommendations. 
 
 Whilst there is overwhelming evidence that higher calcium scores are associated with greater 
cardiovascular risk, at an individual plaque level, studies have shown that calcified plaques 
are more stable and less prone to rupture. This paradox raises questions about the role of 
calcification in the natural history of coronary atherosclerosis and highlights the need to 
assess disease activity within plaques.  
 
Plaque Activity 
Recent advances in hybrid imaging technology combines the high spatial resolution and 
anatomical detail provided by CT with molecular assessment of disease activity provided by 
positron emission tomography (PET). This allows identification of high-risk plaque 
characteristics, the differentiation of active from burnt out stable disease states, with the 
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potential to improve patient risk stratification. With modern PET-CT scanners, accurate co-
registration, improved blood-pool correction and state-of-the-art motion correction have 
facilitated the measurement of disease activity in the coronary arteries (Kwiecinski et al., 
2018; Lassen et al., 2018). This has in turn triggered a growing interest in the development of 
novel tracers targeting specific aspects of plaque biology.  
 
18
F-Sodium fluoride preferentially binds to pathological mineralisation and identifies areas of 
microcalcification which is thought to be an early adaptive response to cell necrosis and 
inflammation that precedes the development of larger macroscopic deposits of calcium that 
can stabilise plaque (Irkle et al., 2013). The increased surface area of microcalcification 
relative to macrocalcification results in increased tracer uptake (Creager et al., 2019). Recent 
evidence demonstrates an inverse correlation between plaque calcium density and tracer 
uptake, with lesions at the lower end of the Hounsfield unit coefficient exhibiting greater 
radioisotope accumulation whilst denser and more highly calcified plaque had relatively 
lower fluoride uptake (Dweck et al., 2012).  
 
18
F-Sodium fluoride is characterised by very low uptake in the myocardium (roughly half to 
two-thirds lower than in the blood-pool) which makes this tracer well suited to the detection 
of signal in the coronary arteries. In patients with stable disease, 
18
F-sodium fluoride uptake 
is associated with multiple adverse features on CT and intravascular ultrasound (Joshi et al., 
2014)
  
. Following acute myocardial infarction, increased 
18
F-sodium fluoride uptake is 
consistently observed within the culprit plaque (Joshi et al., 2014)
  
(Figure 3)
 
. To further 
investigate the clinical utility of 18F-sodium fluoride in the coronary arteries and its role in 
risk prediction, the prospective multicentre PREFFIR (Prediction of Recurrent Events With 
18
F-Fluoride) trial is currently underway (ClinicalTrials.gov NCT02278211). 
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There are some emerging novel tracers that target more specific inflammatory pathways. For 
example, there have been recent reports describing the use of 
68
Ga-dotatate which targets 
somatostatin type 2 receptors that are abundant on the surface of pro-inflammatory 
macrophages. This has been successfully used to identify inflamed coronary artery plaque 
with higher uptake noted  in culprit vessel than in the non-culprit vessels (Tarkin et al., 2017). 
Novel agents that target translocator proteins (TPSO) in macrophages localize to 
atherosclerotic plaques and can quantify plaque macrophage content (Gaemperli et al., 2012). 
In contrast to 
18
F-sodium fluoride, these approaches target the pathological processes and 
pathways that mediate the disease process itself and may therefore be a better indicator of 
disease activity and treatment response. Further clinical research is needed to confirm the role 
of these tracers in the assessment and characterisation of atherosclerotic disease. 
 
One emerging technique for identifying areas of coronary artery inflammation is the 
assessment of perivascular adipose tissue that is thought to interact with adjacent coronary 
atherosclerotic plaque in a bidirectional manner (Antonopoulos et al., 2017). Coronary artery 
and plaque inflammation is thought to alter the composition of the adjacent perivascular 
adipose tissue
 
, an effect that can be detected by subtle changes in CT attenuation 
(Antonopoulos et al., 2017);  (Goeller et al., 2018) (Figure 4). In effect, the composition of 
the perivascular fat provides a proxy of underlying inflammation in the coronary arteries and 
may allow assessment of coronary plaque instability (Antonopoulos et al., 2017). Indeed, the 
technique does correlate well with 18F-sodium fluoride coronary uptake (Kwiecinski et al., 
2019), and appears to identify patients at elevated cardiovascular risk (Mahabadi and Rassaf, 
2018) and predict cardiovascular mortality (Oikonomou et al., 2018). The appeal of cardiac a 
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single coronary CT angiography providing details about coronary anatomy, plaque 
morphology, plaque burden as well as disease activity is undeniable.  
 
CLINICAL CONTEXT 
 
Asymptomatic Individuals 
At present, coronary artery calcium scoring is superior to any combination of traditional risk 
factors and serum biomarkers. In asymptomatic patients, a calcium score of zero has a 
negative predictive value of 95-99% (Sarwar et al., 2009). In these patients, the absence of 
calcium reliably excludes obstructive coronary artery stenosis. Equally, scores >0 confirm the 
presence of coronary atherosclerotic plaque, and increasing scores identify increasing plaque 
burden and increased cardiovascular risk (Detrano et al., 2008). The 2017 Society of 
Cardiovascular Computed Tomography (SCCT) guidelines recommend performing  calcium 
scoring in selected patients with a CVD risk between 5 and 20%  in the context of shared 
decision-making (Hecht et al., 2017). Calcium scoring should also be considered in patients 
with CVD risk <5% who have a with family history of premature coronary heart disease 
(Hecht et al., 2017). Calcium scores can guide the need for lipid lowering therapy. A 
coronary artery calcium score >300 Agatston units is associated with a four-fold higher risk 
of cardiovascular events compared to a calcium score of zero (Lauer, 2007). On this basis, the 
2013 ACC/AHA Guideline on the Management of High Cholesterol (Ray et al., 2014) 
recommended that an Agatston Score of >300 units be used as a modifier to justify statin 
therapy for primary prevention in adults between 40-75 years old without diabetes and with 
LDL-C 70-189 mg/dL. Furthermore, evidence suggests that CAC may also promote long-
term compliance to preventative therapy (Nasir et al., 2010). 
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Although the majority of data to date has focused on symptomatic patients with suspected 
coronary artery disease, the prognostic utility of coronary CT angiography has also been 
assessed in asymptomatic patients.  The CONFIRM Registry (Coronary CT Angiography 
Evaluation for Clinical Outcomes: An International Multicenter Registry) is the largest 
observational study looking at the associations between coronary CT angiography findings 
and their ability to predict mortality and major adverse cardiac events. In a cohort of 
asymptomatic individuals with no previous history of coronary artery disease, the addition of 
coronary CT angiography did not add any incremental benefit over and above the coronary 
artery calcium score and traditional risk score (p=0.423) (Cho et al., 2012). As such, coronary 
CT angiography is not currently recommended as a screening tool in asymptomatic patients 
who are in at low absolute risk of major adverse cardiac events. The current European 
guidelines generally do not recommend routine non-invasive imaging to for risk assessment 
in asymptomatic patients, but suggest that assessment of disease burden (using calcium score 
and carotid ultrasound) may be considered as a risk modifier in cardiovascular risk 
assessment (Piepoli et al., 2016). Conversely, the latest American guidelines for detection and 
risk assessment of coronary artery disease state that calcium scoring and coronary CT 
angiography use “may be appropriate” in asymptomatic patients with high global risk 
(Greenland et al., 2010).  
 
To date there has been only one randomised controlled trial of coronary CT angiography in 
the setting of primary prevention. In the FACTOR 64 trial, 900 high-risk asymptomatic 
patients with long-standing diabetes mellitus were randomised to screening with coronary CT 
angiography (n=452) or guideline-based optimal diabetes care (n = 448) (Muhlestein et al., 
2014). Despite a high prevalence of obstructive disease (23 % with moderate to severe 
luminal stenosis on coronary CT angiography), intention-to-treat analysis showed similar 
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rates of the composite of death, non-fatal MI, and hospitalisation for unstable angina after a 
mean follow-up of 4 years. The majority of patients had well controlled cardiovascular risk 
factors at baseline, with haemoglobin A1C, serum low-density lipoprotein cholesterol 
concentrations, and systolic blood pressure near or exceeding target levels in all participants. 
The addition of coronary CT angiography had no effect on these risk factors although there 
was a very modest greater reduction in serum cholesterol concentrations which may have 
reflected an increase in the use and intensity of statins. Thus, the role of coronary CT 
angiography in primary prevention needs to established and will be the focus of the SCOT-
HEART 2 trial. 
 
Patients with Stable Chest Pain 
Contrast coronary CT angiography is being increasingly used in the clinical assessment of 
patients with suspected coronary artery disease, supported by a growing evidence base. 
Current American College of Cardiology guidelines for stable ischaemic heart disease 
suggest that in symptomatic patients with low to intermediate pre-test probability of CAD, 
CT coronary angiography should be reserved for those with contraindications to stress testing 
(Fihn et al., 2014), and the  European Society of Cardiology guidelines recommend the use of 
CTA as the first line test in symptomatic patients at low-intermediate pre-test probability for 
CAD (Task Force Members et al., 2013). The most recent National Institute for Health and 
Care Excellence (NICE) guidelines in the United Kingdom recommend coronary CT 
angiography as the first line imaging assessment in all patients presenting with typical or 
atypical angina, as well as patients with non-anginal chest pain with associated ECG changes 
(Padley et al., 2017). The clinical utility of coronary CT angiography in the treatment of 
patients presenting with stable chest pain has been investigated in the setting of two major 
randomised controlled trials (Douglas et al., 2015; SCOT-HEART investigators, 2015).   
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The Scottish Computed Tomography of the Heart (SCOT-HEART) trial was a multicentre 
randomised controlled trial of 4,146 patients across Scotland who presented to the cardiology 
clinic with suspected angina pectoris due to coronary heart disease (Douglas et al., 2015; 
SCOT-HEART investigators, 2015). In this trial, the addition of coronary CT angiography 
was compared with standard care alone which included unrestricted access to stress testing 
and invasive angiography in both groups. It demonstrated that the use of coronary CT 
angiography increased diagnostic certainty and improved clinical management.  At a median 
of 4.8 years, the primary endpoint of coronary heart disease death or non-fatal MI was 
reduced by a 41% in patients who underwent CT imaging compared to standard care alone 
(2.3% vs. 3.9%, HR 0.59, 95% CI 0.41-0.84) (SCOT-HEART, 2018). This difference was 
principally driven by a lower rate of non-fatal MI which is most likely due to the more 
accurate diagnosis of both obstructive and non-obstructive coronary heart disease, resulting in 
the more appropriate initiation of preventative therapies and a subsequent reduction in 
adverse events (Williams et al, 2019).  
 
The Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) 
randomised 10,003 participants to coronary CT angiography or functional stress testing in a 
head-to-head comparison (Douglas et al, 2015). It recruited a lower risk population and 
showed that there was no difference in the composite primary outcome (death, non-fatal 
myocardial infarction, hospitalisation for unstable angina, or major procedural complication) 
after a median of 25 months (Douglas et al., 2015).  However, at 12 months, there was a 
reduction in the rate of death and non-fatal myocardial infarction of a similar magnitude to 
the SCOT-HEART trial (34% relative risk reduction). In both these trials, a half or more of 
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the observed myocardial infarctions occurred in patients with non-obstructive disease on their 
baseline scan (Hoffmann et al., 2017). 
 
Further analyses of both the PROMISE and SCOT-HEART cohorts have explored the 
associations between high-risk plaque characteristics and outcomes. In SCOT-HEART, the 
presence of at least one high-risk plaque feature (positive remodelling or low attenuation 
plaque) conferred a 3-fold higher risk of coronary heart disease death or nonfatal myocardial 
infarction (HR 3.01, 95% CI 1.61 – 5.63) (Williams et al., 2019). Similarly,  PROMISE data 
showed that even after adjusting for risk factors and stenosis severity, the presence of high-
risk plaque features is associated with an increased risk of major adverse cardiac events (HR 
1.72, 95% CI 1.89 – 3.93) (Hoffmann et al., 2017). Whilst there is growing evidence 
confirming the association between  high-risk plaque characteristics and outcomes (Nerlekar 
et al., 2018), it is important to keep this in perspective. The positive predictive value of high-
risk plaque is in fact very low as only a minority of patients with high-risk plaque will 
experience major adverse cardiovascular event (Stone et al., 2011; Otsuka et al., 2013).   
 
Patients with Acute Chest Pain 
Whilst the role of cardiac CT in the assessment of stable chest pain is well established, its 
role in improving clinical outcomes in patients with acute chest pain remains unclear.  Acute 
chest pain accounts for 6% of all attendance to the emergency department (Goodacre et al., 
2005), and represents a challenge for attending clinicians due to its broad differential 
diagnosis, and risks of serious morbidity and mortality. Although most patients will be 
admitted for measurement of serial biomarkers and electrocardiograms, less than a quarter of 
these will ultimately be diagnosed with acute coronary syndrome (Body et al., 2011). In light 
of its high negative predictive value, coronary CT angiography may prove useful in this 
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setting. There have been several trials assessing the role of coronary CT angiography in the 
safe and effective discharge of low risk chest pain patients from the emergency department 
(Hoffmann et al., 2012); (Litt et al., 2012).  
 
The ROMICAT II (Rule Out Myocardial Infarction/Ischemia Using Computer Assisted 
Tomography II) trial is a  multicentre, randomized controlled  which enrolled 1000 patients  
with low-risk chest pain presenting to the emergency department and randomised them to 
either coronary CT angiography (n = 501) or standard care (n = 499) (Hoffmann et al., 2012).  
Whilst there were no differences in cardiovascular outcomes, the use of coronary CT 
angiography results in more direct discharges from the emergency department and a lower 
mean length of stay in the hospital. In the CT arm, over a fifth of acute coronary syndrome 
were observed in patients with non-obstructive disease, highlighting once more the 
prognostic significance of non-obstructive disease and the added value of CT imaging of 
high-risk plaque features in these patients. In patients presenting with acute chest pain, the 
presence of any high-risk plaque features is an independent predictor of the presence of acute 
coronary syndrome (Puchner et al., 2014). Furthermore, in patients with confirmed 
myocardial infarction, the non-calcified plaque volume is an independent predictor of further 
major adverse cardiovascular events (Hammer-Hansen et al., 2009). The role of coronary CT 
angiography in high-risk patients including those with changes on the electrocardiogram or 
elevations in cardiac troponin, is the subject of the ongoing RAPID-CTCA trial 
(ISRCTN19102565).  
 
In the era of high sensitivity troponin assays, we are seeing the identification of more patients 
with raised cardiac biomarkers but no evidence of coronary thrombosis. This may be related 
to other cardiac conditions, such as myocarditis, arrhythmia and type 2 myocardial infarction.  
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CT coronary angiography may reduce the need for invasive intervention in some of these 
patients who may otherwise have gone to the catheterisation laboratory. Growing evidence 
supports that non-invasive anatomic testing by coronary CTA alone may prove advantageous 
for promptly and accurately identifying candidates for downstream procedures  (Lee et al., 
2017) (Dewey et al., 2016). 
 
TREATMENT STRATEGIES 
 
Antithrombotic Therapy  
The role of antiplatelet therapies in the management of atherothrombotic disease is well 
established and has been extensively studied. An acute coronary event is often heralded by an 
acute plaque rupture, exposing the subendothelium and activating the clotting cascade, 
thereby leading to localised thrombus formation. Antiplatelet therapies are part of the routine 
standard of care for patients with or at risk of acute coronary events. In addition to its 
antiplatelet effect,  aspirin may prevent coronary thrombotic disease through systemic effects 
resulting in a reduction in pro-inflammatory cytokines (Cyrus et al., 2002). Furthermore,  
aspirin also seems to reduce C-reactive protein level in patients with coronary artery disease, 
a blood biomarker that has been linked to worsening outcomes following myocardial 
infarction (Heeschen et al., 2000). Raised C-reactive protein levels following a myocardial 
infarction may reflect the inflammatory activity of a ruptured plaque (Rioufol and Finet, 
2004) and intensive dual anti-platelet therapy in this setting  may have a stabilising effect. 
 
Plaque vulnerability is a dynamic process and, at any one time, plaques that were previously 
stable may become “vulnerable”. As such, the therapeutic effects of anti-platelet therapy are 
not limited to the acute setting and argue for the early implementation of anti-platelet therapy 
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in patient with both obstructive and non-obstructive disease. This may reduce plaque 
progression and reduce events by mitigating the development of occlusive thrombus 
formation in the presence of a plaque rupture event. 
 
Lipid Lowering Therapy 
The use of lipid lowering therapy in the form of statin is advocated for both primary and 
secondary prevention of cardiovascular disease and has been associated with a mortality 
benefit (Heart Protection Study Collaborative Group, 2002). Statins achieve these benefits 
through plaque stabilisation and slowing plaque progression (Nissen et al., 2006); (Nicholls et 
al., 2010). This is thought to be partly driven by the pro-calcific effects of statin therapy on 
coronary atheroma that is independent of their plaque-regressive effect (Puri et al., 2015) and 
explains why statins appear to increase not decrease the CT calcium score (Houslay et al., 
2006; Dykun et al., 2016); (Schmermund et al., 2006). Furthermore, in patients with unstable 
disease, statins have anti-inflammatory effects that may increase fibrous plaque thickness 
(Komukai et al., 2014); (van der Harst et al., 2004). 
Coronary CT angiography studies have shown that initiation of statin therapy reduces 
progression of noncalcified plaque volume, which accounts for most of the benefits of this 
therapy (Hoffmann et al., 2010); (Li et al., 2016).  This concurs with large randomised trials 
that have demonstrated that the use cardiac CT is associated with a lower rate of myocardial 
infarction and is most likely due to the early targeted initiation of preventative therapies, such 
as statins, in patient with both obstructive and non-obstructive disease (SCOT-HEART 
investigators, 2015). Based on the increased risk of myocardial infarction in patients with 
high-risk plaque features, irrespective of the degree of stenosis, the intensification of statin 
therapy, may be a cost effective and effectual strategy. 
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Proprotein convertase subtilisin–kexin type 9 (PKS9) inhibitors are a newer class LDL-
lowering drugs that reduce LDL cholesterol levels when added to statin therapy (Giugliano 
and Sabatine, 2015).  PCKS9 levels appear to correlate with necrotic core size of non-culprit  
coronary plaques (Cheng et al., 2016) and their inhibition improves plaque morphology  
(Kühnast et al., 2014). This has been confirmed by a reduction in intravascular ultrasound-
determined plaque atheroma volume in patients treated with PCSK9 inhibitors (Puri et al., 
2016). Their modulatory effects on high-risk plaques has yet to be established but would be 
anticipated to have similar beneficial effects to statins.  
 
Anti-inflammatory Therapy 
Various pathways and inflammatory mediators have been implicated in atherosclerotic 
process. Anti-inflammatory medication is anticipated to reduce atherosclerotic burden and 
stabilise atherosclerotic plaques. The Canakinumab Anti-inflammatory Thrombosis 
Outcomes Study (CANTOS) was a randomized, double-blind trial involving 10,061 patients 
and it  showed that that an anti-inflammatory intervention with the monoclonal antibody 
canakinumab confers a reduced risk of atherothrombotic events, reducing cardiovascular 
events in well-treated patients with coronary heart disease (Ridker et al., 2017). This is 
thought to be driven by the reduction in vascular inflammation - as reflected by the reduction 
in tumour necrosis factor-alpha, interleukin-6 and c-reactive protein – since it had no effect 
on serum LDL cholesterol concentrations. However, the Cardiovascular Inflammation 
Reduction Trial (CIRT) showed that low-dose methotrexate did not reduce inflammatory 
mediators, or cardiovascular events compared with placebo among patients with established 
coronary heart disease and diabetes, the metabolic syndrome or both.  
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These trials are a major step forward in exploring the cardiovascular impact of anti-
inflammatory interventions. It is too early to predict how successful these agents will prove in 
the treatm nt of coronary plaques. Further research is needed to better elucidate the complex 
nature of the pathophysiological mechanisms underpinning inflammation and its impact on 
plaque vulnerability, and consequent clinical events. However, it would be interesting to 
explore whether CT-derived measures of perivascular adipose tissue inflammation, or plaque 
vulnerability could be used to guide anti-inflammatory therapies and determine whether they 
could impact on clinical outcomes. 
 
Localised Invasive Treatment 
Our clinical management of coronary atherosclerosis is centred on the identification and 
revascularisation of obstructive disease.  However, whilst stable angina and symptoms of 
cardiac ischemia are associated with severe coronary artery stenoses, the majority of 
myocardial infarctions occur at sites of non-obstructive plaque on antecedent angiography. 
This is supported by a large body of evidence from interventional trials, showing  that  
effective treatment of obstructive disease does not translate to better outcomes through the 
prevention of myocardial infarction (Boden et al., 2007). This suggests that identification of 
obstructive coronary lesions is only one aspect of the complex relationship between 
atherosclerosis and ischaemia. The number of high-risk plaque features appear to increase as 
stenosis severity increase, but the presence of high-risk plaque also remains an independent 
predictor of ischaemia regardless of stenosis severity, particularly positive remodelling (Park 
et al., 2015; Nakazato et al., 2016).  
 
Whilst there is currently no evidence to justify targeted revascularisation of lesions on the 
basis of high-risk plaque features alone, the question remains as to whether the decision to 
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undertake percutaneous coronary intervention should take into account not only the 
haemodynamic significance of the coronary disease but also consider plaque composition. 
There are ongoing trials (PROSPECT-ABSORB, PREVEVENT, PECTUS) looking at the 
preventive local treatment of vulnerable plaques that are using bioabsorbable stents which 
may reduce or eliminate the long-term risk of stent thrombosis: so called “plaque sealing” 
approaches.  Given the low but significant procedural event rates and risks of stent 
thrombosis or restenosis, the concept of stenting mild to moderate non-obstructive lesions 
because they contain vulnerable plaques needs to be convincing proven especially as the 
evidence for stenting obstructive lesions is lacking.  
 
 
CONCLUSION 
 
With advances in scanner technology, it is now possible to image atherosclerotic plaque 
composition and disease activity as well as differentiate stable from unstable patterns of 
disease in the coronary vessels. Coronary CT angiography has proven to be an effective 
method to improve the detection of coronary heart disease and this has had the downstream 
consequences of improving and targeting therapies that are associated with improved 
outcomes such as reductions in non-fatal and fatal myocardial infarction. It is likely that we 
will see its increasing use in the current and future management of patients with suspected 
coronary heart disease across a broad range of clinical areas. 
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Figure 1: Assessment of Luminal Stenosis 
 
(A) Coronary CT angiography of a patient with angina showing mixed plaque and luminal 
stenosis in proximal left anterior descending artery (red arrow). 
(B) Subsequent invasive coronary angiogram demonstrating an obstructive stenosis of the 
proximal left anterior descending artery (blue arrow). 
(C) Coronary CT angiography of a patient with angina showing a tight stenosis of the mid right 
coronary artery (red arrow). 
(D) Subsequent invasive coronary angiogram confirmed a tight stenosis of the mid right 
coronary artery (blue arrow). 
A
cc
ep
te
d 
A
rt
ic
le
 
 
This article is protected by copyright. All rights reserved. 
 
 
 
Figure 2: Assessment of High-risk Plaque Features  
(A) Low attenuation plaque (green arrow) in the proximal left anterior descending artery with 
spotty calcification and associated vessel stenosis 
(B) An atherosclerotic plaque in the right coronary artery with positive remodelling (yellow 
arrow), napkin-ring sign (blue arrow) and spotty calcification (red arrow).  
(C) Non-obstructive plaque in proximal left anterior descending artery with spotty calcification 
(red arrow). 
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Figure 3: Assessment of Disease Activity using Positron Emission Tomography  
(A) Invasive coronary angiography showing a culprit stenosis of the right coronary artery (red 
arrow). 
(B) Intense focal 
18 
F-fluoride uptake (
18
F-NaF, tissue-to-background ratios 2.1) is observed at 
the site of the culprit plaque on the combined positron emission and computed tomogram 
(PET-CT). 
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Figure 4: Perivascular Fat Analysis Around Epicardial Coronary Vessels 
 
Image reproduced from (Oikonomou et al., 2018) 
(A) Perivascular fat attenuation index phenotyping of the proximal segments of all three major 
epicardial coronary vessels, with corresponding fat attenuation index colour maps 
(B) Example of perivascular fat attenuation index phenotyping around the proximal right 
coronary artery. Perivascular fat was defined as fat within a radial distance equal to the 
diameter (d) of the vessel.  
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